{"id":277829,"date":"2024-10-19T18:42:51","date_gmt":"2024-10-19T18:42:51","guid":{"rendered":"https:\/\/pdfstandards.shop\/product\/uncategorized\/bs-iso-29943-22017\/"},"modified":"2024-10-25T15:14:15","modified_gmt":"2024-10-25T15:14:15","slug":"bs-iso-29943-22017","status":"publish","type":"product","link":"https:\/\/pdfstandards.shop\/product\/publishers\/bsi\/bs-iso-29943-22017\/","title":{"rendered":"BS ISO 29943-2:2017"},"content":{"rendered":"
PDF Pages<\/th>\n | PDF Title<\/th>\n<\/tr>\n | ||||||
---|---|---|---|---|---|---|---|
2<\/td>\n | National foreword <\/td>\n<\/tr>\n | ||||||
7<\/td>\n | Foreword <\/td>\n<\/tr>\n | ||||||
8<\/td>\n | Introduction <\/td>\n<\/tr>\n | ||||||
9<\/td>\n | 1 Scope 2 Normative references 3 Terms and definitions <\/td>\n<\/tr>\n | ||||||
11<\/td>\n | 4 Risk assessment 5 Pilot clinical studies <\/td>\n<\/tr>\n | ||||||
12<\/td>\n | 6 Clinical validation investigation 6.1 Objectives of clinical validation investigation 6.2 Outcome measures 6.3 Study subjects 6.3.1 General <\/td>\n<\/tr>\n | ||||||
13<\/td>\n | 6.3.2 Enrolment of study subjects <\/td>\n<\/tr>\n | ||||||
14<\/td>\n | 6.4 Informed consent 6.5 Test and control condoms 6.5.1 General <\/td>\n<\/tr>\n | ||||||
15<\/td>\n | 6.5.2 Test condom 6.5.3 Control condom 6.5.4 Trial duration exceeds one year <\/td>\n<\/tr>\n | ||||||
16<\/td>\n | 6.5.5 Sampling of control condoms for bench testing 6.6 Randomization 6.7 Allocation concealment and study masking 6.8 Use of additional lubricant 6.9 Instructions and interactions with study couples <\/td>\n<\/tr>\n | ||||||
17<\/td>\n | 6.10 Interviews and data collection 6.10.1 Schedule for interviews and condom distribution 6.10.2 Enrolment interview <\/td>\n<\/tr>\n | ||||||
18<\/td>\n | 6.10.3 Individual condom use CRF 6.10.4 Mid-study CRF, crossover trial <\/td>\n<\/tr>\n | ||||||
19<\/td>\n | 6.10.5 Compiling data from CRFs 6.11 Data integrity 6.11.1 General 6.11.2 Interactive voice response systems (IVRS) 6.11.3 Mail-in and web-based data reporting <\/td>\n<\/tr>\n | ||||||
20<\/td>\n | 6.11.4 Web-based data collection systems, additional suggestions <\/td>\n<\/tr>\n | ||||||
21<\/td>\n | 6.12 Control of distribution chain 6.13 Analysis of returned condoms 6.14 Other methodological details <\/td>\n<\/tr>\n | ||||||
22<\/td>\n | 6.15 Statistical analysis plan 6.15.1 General 6.15.2 Primary study hypothesis <\/td>\n<\/tr>\n | ||||||
23<\/td>\n | 6.15.3 Secondary study hypotheses 6.15.4 Study design 6.15.5 Statistical analysis <\/td>\n<\/tr>\n | ||||||
24<\/td>\n | 6.15.6 Additional statistical comments and concerns 6.16 Clinical study results: Review and interpretation 6.16.1 General 6.16.2 Total clinical failure rates for control condom 6.16.3 Non-inferiority <\/td>\n<\/tr>\n | ||||||
25<\/td>\n | 6.16.4 Superiority 6.16.5 Safety (adverse events) 6.16.6 What happens if one is unable to conclude non-inferiority? <\/td>\n<\/tr>\n | ||||||
26<\/td>\n | Annex A (informative) Formula for power calculation <\/td>\n<\/tr>\n | ||||||
27<\/td>\n | Annex B (informative) Pilot clinical investigation (sample outline) <\/td>\n<\/tr>\n | ||||||
29<\/td>\n | Annex C (informative) Time and events schedule for individual study subject (sample) <\/td>\n<\/tr>\n | ||||||
30<\/td>\n | Annex D (informative) CRF \u2014 Study entry (sample) <\/td>\n<\/tr>\n | ||||||
33<\/td>\n | Annex E (informative) CRF \u2014 Mid-study (sample) <\/td>\n<\/tr>\n | ||||||
35<\/td>\n | Annex F (informative) CRF \u2014 Single use of female condom (sample) <\/td>\n<\/tr>\n | ||||||
39<\/td>\n | Annex G (informative) CRF \u2014 Adverse event (sample) <\/td>\n<\/tr>\n | ||||||
41<\/td>\n | Annex H (informative) Protocol for evaluation of returned used condoms <\/td>\n<\/tr>\n | ||||||
47<\/td>\n | Bibliography <\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":" Condoms. Guidance on clinical studies – Female condoms, clinical function studies based on self-reports<\/b><\/p>\n |